Harel Insurance Investments & Financial Services Ltd. lowered its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 0.3% during the second quarter, Holdings Channel reports. The institutional investor owned 1,431,035 shares of the company’s stock after selling 4,470 shares during the period. Teva Pharmaceutical Industries Limited accounts for about 3.8% of Harel Insurance Investments & Financial Services Ltd.’s portfolio, making the stock its 5th largest position. Harel Insurance Investments & Financial Services Ltd.’s holdings in Teva Pharmaceutical Industries Limited were worth $47,539,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sii Investments Inc. WI raised its position in shares of Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Sii Investments Inc. WI now owns 6,739 shares of the company’s stock worth $214,000 after buying an additional 25 shares in the last quarter. Salem Investment Counselors Inc. boosted its stake in Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Salem Investment Counselors Inc. now owns 8,332 shares of the company’s stock worth $267,000 after buying an additional 32 shares during the last quarter. Cribstone Capital Management LLC boosted its stake in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock worth $101,000 after buying an additional 100 shares during the last quarter. Financial Architects Inc boosted its stake in Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock worth $143,000 after buying an additional 100 shares during the last quarter. Finally, Sterling Investment Advisors Ltd. boosted its stake in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares during the last quarter. 56.27% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 17.50 on Thursday. Teva Pharmaceutical Industries Limited has a 52-week low of $17.47 and a 52-week high of $55.39. The company has a 50-day moving average of $30.48 and a 200-day moving average of $31.78. The company’s market cap is $17.78 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same quarter in the previous year, the company posted $1.25 EPS. The business’s quarterly revenue was up 12.9% on a year-over-year basis. On average, equities research analysts expect that Teva Pharmaceutical Industries Limited will post $4.39 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be issued a dividend of $0.085 per share. The ex-dividend date is Friday, August 25th. This represents a $0.34 annualized dividend and a yield of 1.94%. Teva Pharmaceutical Industries Limited’s payout ratio is -18.95%.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stake Cut by Harel Insurance Investments & Financial Services Ltd.” was reported by Daily Political and is the property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/10/teva-pharmaceutical-industries-limited-nyseteva-stake-cut-by-harel-insurance-investments-financial-services-ltd.html.

TEVA has been the topic of a number of analyst reports. Zacks Investment Research raised shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research note on Monday, April 17th. Deutsche Bank AG lowered their target price on shares of Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating on the stock in a research note on Friday, May 12th. Vetr raised shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “strong-buy” rating and set a $34.25 target price on the stock in a research note on Wednesday, May 17th. Citigroup Inc. lowered their target price on shares of Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a “buy” rating on the stock in a research note on Tuesday, April 25th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $38.00 target price (down previously from $42.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Monday, May 15th. Three investment analysts have rated the stock with a sell rating, nineteen have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries Limited presently has a consensus rating of “Hold” and a consensus target price of $37.69.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.